Literature DB >> 17015626

High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.

Florence Doualla-Bell1, Ava Avalos, Bluma Brenner, Tendani Gaolathe, Madisa Mine, Simani Gaseitsiwe, Maureen Oliveira, Daniella Moisi, Ndwapi Ndwapi, Howard Moffat, Max Essex, Mark A Wainberg.   

Abstract

We analyzed the reverse transcriptase genotypes of human immunodeficiency virus type 1 subtype C viruses isolated from 23 patients in Botswana treated with didanosine-based regimens. The K65R mutation was selected either alone or together with the Q151M, S68G, or F116Y substitution in viruses from seven such individuals. The results of in vitro passage experiments were consistent with an apparent increased propensity of subtype C viruses to develop the K65R substitution.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17015626      PMCID： PMC1693987          DOI： 10.1128/AAC.00714-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

Authors:  Bluma G Brenner; Maureen Oliveira; Florence Doualla-Bell; Daniela D Moisi; Michel Ntemgwa; Fernando Frankel; Max Essex; Mark A Wainberg
Journal:  AIDS       Date:  2006-06-12       Impact factor: 4.177

2.  A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.

Authors:  Bluma Brenner; Dan Turner; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Mauricio Carobene; Richard G Marlink; Jonathan Schapiro; Michel Roger; Mark A Wainberg
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

3.  Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).

Authors:  S H Eshleman; G Becker-Pergola; M Deseyve; L A Guay; M Mracna; T Fleming; S Cunningham; P Musoke; F Mmiro; J B Jackson
Journal:  J Infect Dis       Date:  2001-08-13       Impact factor: 5.226

4.  A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.

Authors:  J Gerardo García-Lerma; Hamish MacInnes; Diane Bennett; Patrick Reid; Soumya Nidtha; Hillard Weinstock; Jonathan E Kaplan; Walid Heneine
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000.

Authors:  Saladin Osmanov; Claire Pattou; Neff Walker; Bernhard Schwardländer; Jose Esparza
Journal:  J Acquir Immune Defic Syndr       Date:  2002-02-01       Impact factor: 3.731

6.  Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France.

Authors:  Marie-Laure Chaix; Diane Descamps; Martine Harzic; Véronique Schneider; Christiane Deveau; Catherine Tamalet; Isabelle Pellegrin; Jacques Izopet; Annick Ruffault; Bernard Masquelier; Laurence Meyer; Christine Rouzioux; Françoise Brun-Vezinet; Dominique Costagliola
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

7.  Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001.

Authors:  Joke Snoeck; Kristel Van Laethem; Philippe Hermans; Eric Van Wijngaerden; Inge Derdelinckx; Yoeri Schrooten; David A M C van de Vijver; Stéphanie De Wit; Nathan Clumeck; Anne-Mieke Vandamme
Journal:  J Acquir Immune Defic Syndr       Date:  2004-03-01       Impact factor: 3.731

8.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

9.  K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

Authors:  Birgit T Røge; Terese L Katzenstein; Niels Obel; Henrik Nielsen; Ole Kirk; Court Pedersen; Lars Mathiesen; Jens Lundgren; Jan Gerstoft
Journal:  Antivir Ther       Date:  2003-04

10.  Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.

Authors:  Chris Stone; Mounir Ait-Khaled; Charles Craig; Philip Griffin; Margaret Tisdale
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more
  50 in total

1.  Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

Authors:  Maria L Ekstrand; Anita Shet; Sara Chandy; Girija Singh; Ranjani Shamsundar; Vidya Madhavan; Shanmugam Saravanan; Elsa Heylen; Nagalingeswaran Kumarasamy
Journal:  Int Health       Date:  2011-03       Impact factor: 2.473

2.  Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

Authors:  Maria Mercedes Santoro; Claudia Alteri; Luigi Ronga; Philippe Flandre; Lavinia Fabeni; Fabio Mercurio; Roberta D'Arrigo; Caterina Gori; Guido Palamara; Ada Bertoli; Federica Forbici; Romina Salpini; Evangelo Boumis; Valerio Tozzi; Ubaldo Visco-Comandini; Mauro Zaccarelli; Margriet Van Houtte; Theresa Pattery; Pasquale Narciso; Andrea Antinori; Francesca Ceccherini-Silberstein; Carlo Federico Perno
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-18       Impact factor: 2.205

Review 3.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

Review 4.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Magdalena E Sobieszczyk; Francine E McCutchan; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

5.  Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns.

Authors:  A Waléria-Aleixo; A N Martins; M B Arruda; R M Brindeiro; R M Da-Silva; F F Nobre; D B Greco; A Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

6.  International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.

Authors:  Philip M Grant; Jonathan Taylor; Andrew B Nevins; Vincent Calvez; Anne-Geneviève Marcelin; Marc Wirden; Andrew R Zolopa
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

7.  Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.

Authors:  Dimitrios Coutsinos; Cédric F Invernizzi; Hongtao Xu; Daniela Moisi; Maureen Oliveira; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).

Authors:  Jorge L Martinez-Cajas; Nitika P Pai; Marina B Klein; Mark A Wainberg
Journal:  J Int AIDS Soc       Date:  2009-06-30       Impact factor: 5.396

9.  Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens.

Authors:  Florence Doualla-Bell; Tendani Gaolathe; Ava Avalos; Suzanne Cloutier; Ndwapi Ndwapi; Christina Holcroft; Howard Moffat; Diana Dickinson; Max Essex; Mark A Wainberg; Madisa Mine
Journal:  J Int AIDS Soc       Date:  2009-10-25       Impact factor: 5.396

10.  Two standards of care for HIV: why are Africans being short-changed?

Authors:  Mark A Wainberg
Journal:  Retrovirology       Date:  2009-12-01       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.